HCM
CLB icon

Highbridge Capital Management’s Core Laboratories CLB Stock Holding History

Highbridge Capital Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,600
Closed -$264K – 1549
2017
Q2 		$264K Buy
+2,600
New +$280K ﹤0.01% 1006
2016
Q4 		– Sell
-8,185
Closed -$920K – 1289
2016
Q3 		$920K Buy
+8,185
New +$943K 0.01% 594

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WP
Wedgewood Partners St Louis, Missouri $484M AUM 16.04% 1-Year Est. Return

Highbridge Capital Management's CLB Position: Q3 2017 in Review

Highbridge Capital Management sold out of Core Laboratories (CLB) in Q3 2017, closing a stake of 2,600 shares — an estimated $264K sold.

Highbridge Capital Management first reported a position in CLB in Q3 2016 and held it in 2 quarters. The position peaked at $920K in Q3 2016. 345 funds tracked by Wall St. Rank hold CLB as of Q3 2017.

  • Highbridge Capital Management reported no remaining Core Laboratories position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 2,600 Core Laboratories shares in Q3 2017, an estimated $264K.
  • Highbridge Capital Management first reported a position in Core Laboratories in Q3 2016 and held it in 2 quarters.
  • Highbridge Capital Management's Core Laboratories position peaked at $920K in Q3 2016.
  • 345 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.